Cyclic peptides open new drug frontiers, if manufacturing can keep up

Cyclic peptides are gaining momentum as a drug modality, but manufacturing limitations are hindering progress.

Cyclic peptides are opening new frontiers in drug development, offering the convenience of small molecules and the selectivity of antibodies.

However, their progress is being slowed by low bioavailability, limited pharmacokinetic data, and fragile synthesis methods.

Experts at Viva Biotech are working to address these challenges through the use of hybrid synthesis, ADME/PK modeling, and AI-guided design.